Cancer Clinical Trial
— CAP'ONCOOfficial title:
CAP'Onco : Psychological and Social Consultation of Professional Accompaniment in Oncology
Verified date | May 2021 |
Source | Institut Bergonié |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This patient support system is designed to help patients regain their professional activity after their treatment. It's a 3-Axis neuropsycho-social synergy on 3 axes: - A weekly pluridisciplinary consultation in tandem (Social worker + Psychologist / Neuropsychologist) - Monthly information meetings and workshops (TIC'Onco reunions: collective information times and Cogit'Onco workshops: cognitive workshops - An information booklet "Prepare the work return" The aim of this research is to evaluate efficiency in term of quality of life improvement linked to work status, utility, feasibility and patients' satisfaction. The aim of this research is to evaluate efficiency in term of quality of life improvement linked to work status, utility, feasibility and patients' satisfaction.
Status | Completed |
Enrollment | 29 |
Est. completion date | June 27, 2018 |
Est. primary completion date | June 27, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 55 Years |
Eligibility | Inclusion Criteria: - Patients attending the Institut BergoniƩ - Informed Consent signed. - Patients affiliated to a French social - living in Gironde - Professional activity at the time of diagnosis - Treated for - breast cancer, Hodgkin's or non-Hodgkin's lymphoma (non-cerebral), testicular cancer - CURATIVE support - At any time during treatment (chemotherapy or radiotherapy, or immunotherapy) Exclusion Criteria: - Patient deprived of liberty or subject to a legal protection measure - History of cancers - Cerebral pathology and / or brain metastasis |
Country | Name | City | State |
---|---|---|---|
France | Institut Bergonié | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
Institut Bergonié |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of Life : EORTC QLQ-C30 Scores | Standardised QLQ-C30 scoring according to EORTC scoring manual (Fayers et al. EORTC QLQ-C30 scoring manual. 2001). 15 dimensions are presented below. Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health. |
At baseline and 5 months | |
Primary | Cognitive Complaints : FACT Cog Scale Scores | Cognitive complaints were evaluated by using the french Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale version 3 Assessed using median total score (range 0-132) and median scores of these 4 dimensions : Perceived Cognitive Impairment (range 0-72) Impact on quality of life (range 0-16) Comments from others (range 0-16) Perceived Cognitive Skills (range 0-28) Higher scores indicate better cognitive functioning. |
At baseline and 5 months | |
Primary | Professional Recovery Scale Scores | Professional recovery was evaluated by using the Scale of motivation to Professional recovery. This scale was constructed for the needs of this exploratory research and has for vocation a later validation. It includes 62 questions and was assessed using median scores of these 7 dimensions : Work and administrative process (0-100) Positioning in relation to the job-post-mission (0-100) Emotion and work (0-100) Labour relations (0-100) Work and physical/intellectual conditions (0-100) Privacy and work (0-100) Return to work (0-20) Higher scores represent better outcomes |
At baseline and 5 months | |
Secondary | Tiredness : Piper MFI-20 Scale Scores | Tiredness was evaluated by using the Piper Multidimensional Fatigue Inventory (MFI-20) revised scale Assessed using median total score (range 0-10) and median scores of these 4 tiredness dimensions : Behavioural Emotional Sensory Cognitive-mood Each dimension has range 0-10 with following interpretation: higher scores indicate greater severity of fatigue |
At baseline and 5 months | |
Secondary | Anxio-depressive Troubles : HAD Scale Scores | Anxio-depressive troubles were evaluated by using the Hospital Anxiety and Depression (HAD) scale. Assessed using median scores of these 2 dimensions : Anxiety Depression Each dimension has range 0-21 with following interpretation: higher scores represent worse outcomes (0-7 normal; 8-10 mild; 11-14 moderate; 15-21 severe) |
At baseline and 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|